IGRA

IGRA stands for Interferon-Gamma Release Assay, a blood test that detects whether a person has been infected with tuberculosis (TB) bacteria. Unlike traditional TB skin tests, IGRAs measure the immune system's response by detecting interferon-gamma, a protein released by white blood cells when they encounter TB antigens in a test tube. The test is more specific than older methods and less prone to false positives from vaccination with the BCG vaccine, making it a valuable modern diagnostic tool.

IGRAs are primarily used in clinical medicine, immunology, and infectious disease research, with applications in public health screening and occupational health programs. The test is particularly important in developed countries where TB vaccination rates are low, and it has become a standard diagnostic method recommended by the CDC, WHO, and other health organizations. Understanding IGRA performance matters because TB remains a leading infectious disease killer globally, and accurate diagnosis is crucial for timely treatment and preventing transmission.

The test works by stimulating a patient's white blood cells with TB-specific antigens in a laboratory setting, then measuring how much interferon-gamma they produce—a sign that the immune system recognizes TB bacteria. Think of it like showing a security guard a suspect's photo: if the guard reacts strongly, it means they've seen that person before. A strong interferon-gamma response indicates TB infection, either active disease or latent infection, while a weak response suggests the person is not infected.

IGRAs are significant because they improve TB diagnosis accuracy, reduce unnecessary treatment of false-positive cases, and help identify people with latent TB infection who might benefit from preventive therapy. As TB drug resistance increases globally, having reliable diagnostic tools like IGRA becomes even more critical for controlling outbreaks and ensuring appropriate clinical interventions.